IMMUCELL CORP /DE/ (ICCC): restructuring charge — ImmuCell reports Q4 sales down 1.6% YoY; records $3.6M impairment, pauses Re-Tain

IMMUCELL CORP /DE/

2025-FY EPS reported -$0.12 revenue$27,644,174

Q4 total sales $7.6M (-1.6% YoY); domestic sales up 8.7%, international down 52.6%.
FY 2025 total sales $27.6M (+4.3% YoY); Tri-Shield sales $19.9M (+26.5%), Dual-Force $6.9M (-27.4%).
Records $3.6M non-cash impairment: $2.9M Re-Tain PPE, $0.1M other PPE, $0.6M colostrum inventory write-down.
Pausing Re-Tain investment after FDA Incomplete Letter; repurposing $15.5M Re-Tain assets for First Defense.
Tri-Shield sales exceed expectations; expanding sales force by 50% with new U.S. territories and international hire.

item 2.02 item 2.06 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

IMMUCELL CORP /DE/ announced a impairment with charges of approximately $2.9 million affecting Re-Tain®.

Type: impairment
Charge: approximately $2.9 million
Affected area: Re-Tain®

Exact text from the filing

The resulting non-cash impairment write-down of property, plant and equipment pertaining to Re-Tain® is currently estimated at approximately $2.9 million

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

IMMUCELL CORP /DE/ announced a impairment with charges of $0.6 million write-down affecting work-in-process colostrum inventory.

Type: impairment
Charge: $0.6 million write-down
Affected area: work-in-process colostrum inventory

Exact text from the filing

a $0.6 million write-down primarily of work-in-process colostrum inventory that was determined to no longer be fit for processing into First Defense®

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

IMMUCELL CORP /DE/ announced a impairment with charges of approximately $3.6 million in non-cash impairment write-downs affecting Re-Tain® assets and other property, plant and equipment and inventory.

Type: impairment
Charge: approximately $3.6 million in non-cash impairment write-downs
Affected area: Re-Tain® assets and other property, plant and equipment and inventory

Exact text from the filing

the Company announced that it will record approximately $3.6 million in non-cash impairment write-downs during the three-month period ended December 31, 2025.

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

IMMUCELL CORP /DE/ announced a impairment with charges of $0.1 million, non-cash impairment write-down affecting certain property, plant and equipment, unrelated to Re-Tain®.

Type: impairment
Charge: $0.1 million, non-cash impairment write-down
Affected area: certain property, plant and equipment, unrelated to Re-Tain®

Exact text from the filing

the Company has identified a $0.1 million, non-cash impairment write-down of certain property, plant and equipment

View on SEC.gov

Browse all restructurings & charges →

IMMUCELL CORP /DE/ filing history →

Source: SEC EDGAR

accession 0001437749-26-000885

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.